Literature DB >> 29792971

Impact of active surveillance and infection control measures on carbapenem-resistant Gram-negative bacterial colonization and infections in intensive care.

T Karampatakis1, K Tsergouli2, E Iosifidis3, C Antachopoulos3, A Karapanagiotou4, A Karyoti5, N Gritsi-Gerogianni4, A Tsakris6, E Roilides7.   

Abstract

BACKGROUND: Carbapenem-resistant Gram-negative bacteria (CRGNB) infections constitute a global threat for critically ill patients and the outcome of their hospitalization. Early identification of CRGNB through rectal surveillance cultures and routine infection control measures including contact precautions, use of appropriate disinfectants, staff education on cleaning, and hand hygiene may reduce the dissemination of CRGNB. AIM: To assess the impact of enhanced infection control measures on CRGNB infections in a nine-bed polyvalent intensive care unit in a tertiary level hospital in an endemic area.
METHODS: A quasi-experimental study, which included patients with CRGNB infection retrospectively for six months and those participating in an active surveillance programme prospectively for the subsequent 22 months. Active surveillance programme (weekly rectal swabs) was implemented including two sub-periods with infection control measures and enhanced infection control measures. CRGNB incidence, prevalence, colonization pressure, infections and compliance with infection control measures and enhanced infection control measures were recorded. Analysis was performed through time-series and interrupted time-series.
FINDINGS: During the active surveillance programme, enhanced infection control measures led to a steeper downwards trend in incidence, prevalence, and colonization pressure for CRGNB compared to the infection control measures sub-period. The linear trend was for carbapenem-resistant Klebsiella pneumoniae (CRKP) and Pseudomonas aeruginosa (CRPA) infections to decrease from 19.6 to 8.1 infections per 1000 bed-days (IBD) (P = 0.001) and from 5.1 to 1.79 IBD (P = 0.043), respectively. By contrast, carbapenem-resistant Acinetobacter baumannii infections increased from 5.2 to 15.3 IBD (P = 0.001).
CONCLUSION: Enhanced infection control measures including enhanced hand hygiene, active surveillance combined with contact precautions, education, audits and feedback policies and interventions could reduce CRKP and CRPA in endemic areas.
Copyright © 2018 The Healthcare Infection Society. All rights reserved.

Entities:  

Keywords:  Active surveillance programme; Carbapenem resistance; Gram-negative bacteria; Infection control measures; Intensive care unit

Mesh:

Substances:

Year:  2018        PMID: 29792971     DOI: 10.1016/j.jhin.2018.05.010

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  9 in total

1.  Carbapenem-resistant Klebsiella pneumoniae-impact of infection-prevention and control interventions.

Authors:  Isabelle Vock; Sarah Tschudin-Sutter
Journal:  Ann Transl Med       Date:  2019-12

2.  Prevention and control of intensive care unit-acquired carbapenem-resistant Klebsiella pneumoniae: need for a multimodal approach.

Authors:  Arta Karruli; Roberto Andini; Antonio Corcione; Emanuele Durante-Mangoni
Journal:  Ann Transl Med       Date:  2019-12

3.  Clonal spread of carbapenemase-producing Enterobacteriaceae in a region, China.

Authors:  Changfu Yin; Weiwei Yang; Yuanpeng Lv; Peng Zhao; Jiansheng Wang
Journal:  BMC Microbiol       Date:  2022-03-29       Impact factor: 3.605

4.  A five-component infection control bundle to permanently eliminate a carbapenem-resistant Acinetobacter baumannii spreading in an intensive care unit.

Authors:  Marianna Meschiari; José-María Lòpez-Lozano; Vincenzo Di Pilato; Carola Gimenez-Esparza; Elena Vecchi; Erica Bacca; Gabriella Orlando; Erica Franceschini; Mario Sarti; Monica Pecorari; Antonella Grottola; Claudia Venturelli; Stefano Busani; Lucia Serio; Massimo Girardis; Gian Maria Rossolini; Inge C Gyssens; Dominique L Monnet; Cristina Mussini
Journal:  Antimicrob Resist Infect Control       Date:  2021-08-19       Impact factor: 4.887

5.  Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study.

Authors:  Qiqiang Liang; Juan Chen; Yongshan Xu; Yibing Chen; Man Huang
Journal:  Antimicrob Resist Infect Control       Date:  2022-06-22       Impact factor: 6.454

6.  Spread of Carbapenem-Resistant Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?

Authors:  Laura Magnasco; Malgorzata Mikulska; Daniele Roberto Giacobbe; Lucia Taramasso; Antonio Vena; Chiara Dentone; Silvia Dettori; Stefania Tutino; Laura Labate; Vincenzo Di Pilato; Francesca Crea; Erika Coppo; Giulia Codda; Chiara Robba; Lorenzo Ball; Nicolo' Patroniti; Anna Marchese; Paolo Pelosi; Matteo Bassetti
Journal:  Microorganisms       Date:  2021-01-03

7.  Comparison of Carbapenem-Resistant Klebsiella pneumoniae Strains Causing Intestinal Colonization and Extraintestinal Infections: Clinical, Virulence, and Molecular Epidemiological Characteristics.

Authors:  Wenli Liao; Na Huang; Ying Zhang; Yao Sun; Tao Chen; Weiliang Zeng; Liqiong Chen; Hong Wen; Jianming Cao; Tieli Zhou
Journal:  Front Public Health       Date:  2021-12-03

Review 8.  Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from Endemic Hospitals?

Authors:  Filippo Medioli; Erica Bacca; Matteo Faltoni; Giulia Jole Burastero; Sara Volpi; Marianna Menozzi; Gabriella Orlando; Andrea Bedini; Erica Franceschini; Cristina Mussini; Marianna Meschiari
Journal:  Antibiotics (Basel)       Date:  2022-07-28

9.  Validation and Extrapolation of a Multimodal Infection Prevention and Control Intervention on Carbapenem-Resistant Klebsiella pneumoniae in an Epidemic Region: A Historical Control Quasi-Experimental Study.

Authors:  Yunqi Dai; Tianjiao Meng; Xiaoli Wang; Bin Tang; Feng Wang; Ying Du; Yuzhen Qiu; Jialin Liu; Ruoming Tan; Hongping Qu
Journal:  Front Med (Lausanne)       Date:  2021-07-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.